NDA 50298, held by Glaxosmithkline. Carbenicillin Disodium.
As of Nov 13, 2026, NDA 50298 (Pyopen), held by Glaxosmithkline, was not approved, with 0 approved supplements and 0 published complete response letters.
| PyopenEQ 1GM BASE/VIAL · injectable;injection | Carbenicillin Disodium | Discontinued |
| PyopenEQ 2GM BASE/VIAL · injectable;injection | Carbenicillin Disodium | Discontinued |
| PyopenEQ 5GM BASE/VIAL · injectable;injection | Carbenicillin Disodium | Discontinued |
| PyopenEQ 10GM BASE/VIAL · injectable;injection | Carbenicillin Disodium | Discontinued |
| PyopenEQ 20GM BASE/VIAL · injectable;injection | Carbenicillin Disodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters